, Volume 45, Supplement 3, pp 46–53 | Cite as

Postmarketing Surveillance of Quinolones, 1990 to 1992

  • Peter Davey
  • Tom McDonald
State-of-The-Art Presentations


During the last 2 years, the major event in the postmarketing surveillance of quinolones has been the worldwide withdrawal of temafloxacin after only 15 weeks on the USA market. The Adverse Drug Reaction (ADR) reports that led to the withdrawal have been reviewed and show that the frequency and type of ADR and serious ADR were highly unusual in comparison with other quinolones marketed in the USA (ciprofloxacin, norfloxacin and ofloxacin). The difficulty in establishing causality between drugs and ADRs is discussed. Prescription event monitoring and computerised databases are beginning to reach the size required to pick up rare ADRs but, even so, they can only establish association rather than causality. Perhaps a more important question is the issue of acceptable risk. This requires better definition in order to apply decision analysis to the options available for the treatment of bacterial infections.


Quinolones Norfloxacin Cefaclor Enoxacin Serum Sickness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cantekin EI, McGuire TW, Griffith TL. Antimicrobial therapy for otitis media with effusion (‘secretory’ otitis media). Journal of the American Medical Association 266: 3309–3317, 1991PubMedCrossRefGoogle Scholar
  2. Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Archives of Internal Medicine 147: 85–88, 1987PubMedCrossRefGoogle Scholar
  3. Christ W, Esch B. Nutzen-Risiko-Abwagung bei Antiinfektiva aus der Sicht der Zulassungsbehorde. Infection 19 (Suppl. 1): S65–S71, 1991PubMedCrossRefGoogle Scholar
  4. CSM. Convulsions due to quinolone antimicrobial agents. Committee on Safety of Medicines Current Problems 32: 1991Google Scholar
  5. Davey PG. Post-marketing surveillance of the quinolones: a view from Great Britain. Reviews of Infectious Diseases 11 (Suppl. 2): 1402–1407, 1989CrossRefGoogle Scholar
  6. Davey PG, McDonald T, Lindsay G. Post-marketing surveillance of quinolones 1988–1990. European Journal of Clinical Microbiology and Infectious Diseases (Special Issue): 164–169, 1991Google Scholar
  7. Davey PG, Parker SE, Malek MM. Pharmacoeconomics of antibacterial treatment. PharmacoEconomics, in press, 1993Google Scholar
  8. Editorial. Zantac leads in US. Scrip 1669: 25, 1991Google Scholar
  9. Editorial. Temafloxacin — anatomy of a withdrawal. Scrip 1737: 20–21, 1992aGoogle Scholar
  10. Editorial. Temafloxacin lesson for CTs. Scrip 1730: 25, 1992bGoogle Scholar
  11. Esch B, Paeschke N, Christ W, Kreutz G. Dokumentation und Bewertung von Arzneimttelnebenwirkungen am Beispiel des Ofloxacins. Infection 19 (Suppl. 1): S9–S12, 1991PubMedCrossRefGoogle Scholar
  12. Hall GC, Luscombe DK, Walker SR. Post-marketing surveillance using a computerised general practice data base. Pharmaceutical Medicine 2: 345–351, 1988Google Scholar
  13. Hallas J, Gram LF, Grodum E, Damsbo N, Brosen K, et al. Drug related admissions to medical wards: a population based survey. British Journal of Clinical Pharmacology 33: 61–68, 1992PubMedCrossRefGoogle Scholar
  14. Inman W, Kubota K, Pearce G, Wilton L. Ciprofloxacin: prescription event monitoring report no. 4. Drug Safety Research Unit, Bursledon Hall 5038BA, Southampton, 1992Google Scholar
  15. Ispahani P, Pearson NJ, Greenwood D. An analysis of community and hospital acquired bacteraemia in a large teaching hospital in the United Kingdom. Quarterly Journal of Medicine 63: 427–440, 1987PubMedGoogle Scholar
  16. Jick H, Jick S, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. British Medical Journal 302: 766–768, 1991PubMedCrossRefGoogle Scholar
  17. Kucers A, Bennett NMcK, Kemp RJ (Eds). The use of antibiotics, 4th ed., William Heinemann, London, 1987Google Scholar
  18. Kuder JM. How much may safety cost? Iatrogenics 1: 33–37, 1991Google Scholar
  19. Launer M. Drugs in focus: 2. Clozapine. Prescribes Journal 32: 70–73, 1992Google Scholar
  20. Petri H, Urquhart J, Herings R, Bakker A. Characteristics of patients prescribed three different inhalational beta-2 agonists: an example of the channeling phenomenon. Postmarketing Surveillance 5: 57–66, 1991Google Scholar
  21. Pichichero ME, Disney FA, Talpey WB. Adverse and beneficial effects of immediate treatment of Group A beta-haemolytic streptococcal pharyngitis with penicillin. Pediatric Infectious Disease Journal 6: 635–643, 1987PubMedCrossRefGoogle Scholar
  22. Platt R, Dreis MW, Kennedy DL, Kuritsky JN. Serum sickness like reactions to amoxicillin, cefaclor, cephalexin and trimethoprim-sulfamethoxazole. Journal of Infectious Diseases 158: 474–477, 1988PubMedCrossRefGoogle Scholar
  23. Pullar R, Wright V, Feely M. What do patients and rheumatologists regard as an ‘acceptable’ risk in the management of rheumatic diseases? British Journal of Rheumatology 29: 215–218, 1990PubMedCrossRefGoogle Scholar
  24. Rawson NSB, D’Arcy G. ‘Validity’ and reliability: idealism and reality in the use of computerized health care databases for pharmacoepidemiological research. Postmarketing Surveillance 5: 31–55, 1991Google Scholar
  25. Tallis R, Hall G, Graig I, Dean A. How common are epileptic seizures in old age? Age and Ageing 20: 442–448, 1991PubMedCrossRefGoogle Scholar
  26. Thompson MS. Willingness to pay and accept risk to cure chronic disease. American Journal of Public Health 76: 392–396, 1986PubMedCrossRefGoogle Scholar
  27. Thornton JG, Lilford RJ, Johnson N. Decision analysis in medicine. British Medical Journal 304: 1099–1103, 1992PubMedCrossRefGoogle Scholar
  28. Tubert P, Begaud B, Haramburu F, Pere JC. Spontaneous reporting: how many cases are required to trigger a warning? British Journal of Clinical Pharmacology 32: 407–408, 1991PubMedCrossRefGoogle Scholar
  29. Waller PC, Wood SM, Langman MJS, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. British Medical Journal 304: 1470–1472, 1992PubMedCrossRefGoogle Scholar

Copyright information

© ADIS International Limited 1993

Authors and Affiliations

  • Peter Davey
    • 1
  • Tom McDonald
    • 1
  1. 1.Department of Pharmacology and Clinical PharmacologyNinewells Hospital and Medical SchoolDundeeScotland

Personalised recommendations